Hatch-Waxman at 40: A Critical Examination of its Past and Future

Foley partner David Rosen, co-chair of the firm’s FDA Practice Group is speaking in the Food and Drug Law Institute’s (FDLI) webinar titled “Hatch-Waxman at 40: A Critical Examination of its Past and Future” on September 24.

This webinar will celebrate the 40th anniversary of the Hatch-Waxman Act — an influential piece of legislation that has been crucial in advancing medical innovation and making generic drugs more accessible to patients.